Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as
goserelin and leuprolide, may stop the adrenal glands from making androgens. Giving
docetaxel and leuprolide or goserelin before surgery may make the tumor smaller and reduce
the amount of normal tissue that needs to be removed. It is not yet known whether giving
docetaxel and leuprolide or goserelin before surgery is more effective than surgery alone in
treating patients with prostate cancer.
PURPOSE: This randomized phase III trial is studying docetaxel and leuprolide or goserelin
to see how well they work when given before surgery compared with surgery alone in treating
patients with high-risk localized prostate cancer.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.